17 completed, 1 terminated. 9 Phase 3, 5 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 8, Terminated 1 |
| Phase 4 | 5 | Completed 5 |
| Not applicable | 1 | Completed 1 |
Follow Xalacom: new trials by email Literature Review of Xalacom trials Research Report on Xalacom
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients T2347, Xalacom - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Laboratoires Thea | 242 | 2014-12-01 | 2017-04-28 |
| Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy Travoprost/timolol therapy, Latanoprost/Timolol therapy - Glaucoma | Phase 4 | Completed | Aristotle University Of Thessaloniki | 42 | 2012-01-01 | 2014-05-12 |
| Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG travoprost and timolol maleate fixed combination, latanoprost and maleate timolol fixed combination, bimatoprost and timolol maleate fixed combination - Uveitis, Anterior, Cystoid Macular Edema | Phase 4 | Completed | University of Campinas, Brazil | 69 | 2011-10-01 | 2013-11-07 |
| Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension Latanoprost-timolol maleate fixed combination ophthalmic solution - Glaucoma, Ocular Hypertension | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 661 | 2010-10-01 | 2023-06-01 | |
| DuoTrav APS Versus XALACOM® in Ocular Surface Health DuoTrav APS, Xalacom - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Terminated | Alcon Research | 240 | 2010-03-01 | 2012-07-19 |
| Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom XALACOM, Duotrav, Ganfort - Glaucoma, Ocular Hypertension | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2015 | 2010-02-01 | 2021-02-02 | |
| A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma DuoTrav (travoprost-timolol ophthalmic drops), Xalacom (latanoprost-timolol ophthalmic drops) - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Ophthalmic Consultants Centres, Canada | 54 | 2009-01-01 | 2015-04-21 |
| Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy. Xalacom - Glaucoma, Open-angle | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 457 | 2008-10-01 | 2021-02-18 | |
| A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH). Xalatan, Xalacom - Glaucoma, Ocular Hypertension | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 300 | 2006-11-14 | 2021-09-08 |
| Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension latanoprost 0.005% + timolol 0,5% fixed combination, brimonidine 0,2% + timolol 0,5% fixed combination - Retina, Ocular Physiology | Not applicable | Completed | Medical University of Vienna | 16 | 2006-01-01 | 2014-11-14 |
| A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma Xalacom, Xalatan, Timolol - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 528 | 2005-12-01 | 2021-02-18 |
| Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION - Glaucoma, Primary Open Angle (POAG), Ocular Hypertension | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 396 | 2005-09-01 | 2021-02-18 |
| A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma Xalacom, Cosopt - Glaucoma, Open Angle, Ocular Hypertension | Phase 4 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 238 | 2005-07-01 | 2021-02-18 |
| A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma Xalacom, Xalatan, Timolol - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 500 | 2005-07-01 | 2021-02-21 |
| Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension Xalacom, unfixed Latanoprost and Timolol - Glaucoma, Open Angle, Ocular Hypertension | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 240 | 2005-06-01 | 2021-02-18 |
| Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh. Xalacom - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 250 | 2003-05-01 | 2021-02-21 |
| A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension Xalacom - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Pfizer | 976 | 2002-02-01 | 2008-11-05 |
| A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients i. Fixed combination of latanoprost 0.005% and timolol 0.5%, timolol 0.5% ophthalmic solution, latanoprost 0.005% ophthalmic solution - Ocular Hypertension, Glaucoma | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 436 | 1997-08-01 | 2021-02-21 |
Ocular Hypertension (14) · Glaucoma, Open-Angle (12) · Glaucoma (8) · Macular Edema (1) · Uveitis, Anterior (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (11) · Alcon Research (1) · Aristotle University Of Thessaloniki (1) · Laboratoires Thea (1) · Medical University of Vienna (1) · Ophthalmic Consultants Centres, Canada (1) · Pfizer (1) · University of Campinas, Brazil (1)
France (4) · Germany (3) · Greece (3) · Italy (3) · Belgium (2) · Canada (2) · Sweden (2) · United States (2) · Australia (1) · Austria (1) · Brazil (1) · China (1) · Denmark (1) · Ireland (1) · Japan (1)
Alana M Santana, MD (1) · David B Yan, MD (1) · Ingeborg Stalmans, Professor (1) · Michael Wolzt, MD (1) · Navroop Gill, OD (1)
PMID 11589866, PMID 14736774, PMID 14996520, PMID 17415690, PMID 18826749, PMID 20142538, PMID 20346127, PMID 21851642, PMID 9098273